Actos became a worldwide, top-selling drug for treatment of Type II diabetes. But the complaint for this class action claims that it increases the risk of bladder cancer—and that the companies involved in developing and promoting the drug knew about this and concealed it.
When you go for an eye treatment for worsening vision, you don’t expect the treatment to leave you blind in that eye. Yet for once the drug used for treatment doesn’t seem to be at fault, and we’re currently investigating what the problem might be.
This class action lawsuit claims that CaremarkPCS Health does not have adequate policies and procedures to ensure that certain specialty drugs, including Enbrel, are maintained within the drugs’ required temperature range during storage and distribution, therefore reducing the quality of the drugs.
Invokana, Invokamet, Jardiance, Xigduo XR, Farxiga, and Glyxambi are drugs used to treat Type 2 diabetes. An investigation is now looking into possible connections between these drugs and a serious condition called ketoacidosis.
This mass tort investigation alleges that the diabetes drug Onglyza can raise the risk of pancreatic cancer in patients and cause heart failure and death. Onglyza is made by AstraZeneca and has been approved by the FDA for the treatment of Type 2 diabetes.